Relmacabtagene Autoleucel: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Study summary
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Signed informed consent
2. Patients who have been treated with Relma-cel, including those who have received off-label products;
3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
Exclusion Criteria:
1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.
Primary outcome measure(s)
ORR — 15 years Percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR);
Trial sites (2)
Facility
City
Region
Status
Beijing Cancer Hospital
Beijing
Beijing Municipality
Peking University International Hospital
Beijing
Beijing Municipality
More Shanghai Ming Ju Biotechnology Co., Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.